Alnylam Pharmaceuticals, Inc (ALNY)

Alnylam Pharmaceuticals' stock (ALNY) has experienced significant growth and some fluctuations. The stock price increased by 73.87% from November 25, 2024, to November 21, 2025, and by 75.42% over the last 12 months. Key events impacting the stock include strong earnings reports, increased revenue guidance, FDA approvals and label expansions, and insider sales. Alnylam reported a robust Q1 2025 with net product revenues up 28% year-over-year, driven by Amvuttra, Givlaari, and Oxlumo. Q2 2025 saw total net product revenues of $672 million, a 64% year-over-year growth, with the TTR franchise revenue increasing by 77%. In Q3 2025, total net product revenues reached $851 million, a 103% year-over-year growth, primarily from the TTR franchise, which grew by 135%. The FDA's acceptance of Alnylam's supplemental new drug application (sNDA) for Amvuttra to treat ATTR amyloidosis with cardiomyopathy (ATTR-CM) and its subsequent approval in Q1 2025 were positive catalysts. The approval of Qfitlia (fitusiran) in the U.S. also contributed to positive sentiment. On November 20, 2025, ALNY experienced a 3.25% decline in its stock price following an insider sale of 12,128 shares by an EVP, valued at $5.45 million.

Based on available information, there is no explicit indication of significant demand seasonality for Alnylam Pharmaceuticals' products and services. The company has consistently reported strong year-over-year growth in product revenues and patient uptake for its RNAi therapeutics, such as Amvuttra, Givlaari, and Oxlumo. This suggests a steady and growing demand driven by medical need rather than seasonal fluctuations.

Alnylam Pharmaceuticals is a biopharmaceutical company focused on RNA interference (RNAi) technology to develop innovative medicines. The company's core business revolves around harnessing RNAi to silence disease-causing genes, offering a novel approach to treating debilitating diseases. Alnylam's major marketed products include ONPATTRO, AMVUTTRA, GIVLAARI, OXLUMO, Leqvio, and Qfitlia. The company also maintains a robust pipeline of investigational RNAi therapeutics targeting both rare and prevalent diseases.

Alnylam Pharmaceuticals is headquartered in Cambridge, Massachusetts, U.S., and has an expanding global presence with additional offices and subsidiaries across various regions. Its international offices are located in Norton, Massachusetts (U.S.), Maidenhead (U.K.), Zug (Switzerland), Amsterdam (Netherlands), Tokyo (Japan), Brazil, Paris (France), Milan (Italy), and Stockholm (Sweden). Alnylam operates subsidiaries in Europe, North America, and Asia-Pacific.

Alnylam Pharmaceuticals has maintained a positive brand reputation, highlighted by its recognition as a "Best Workplace for Innovators" by Fast Company for the fifth consecutive year. Alnylam's reputation is also built on its pioneering role in RNAi therapeutics and its dedication to addressing unmet medical needs through patient advocacy. An insider sale event on November 20, 2025, led to a short-term stock price dip and raised questions about "short-term governance perceptions", but it was not widely reported as a significant, lasting negative impact on the company's overall brand reputation.

Alnylam Pharmaceuticals, Inc. has a diverse ownership structure, predominantly held by institutional investors. Approximately 82.86% to 99.36% of the company's stock is owned by institutional investors. Insider ownership is relatively low, around 0.42% to 0.46%. Major institutional owners of Alnylam Pharmaceuticals include Fmr Llc, Capital World Investors, Vanguard Group Inc, BlackRock, Inc., Capital Research Global Investors, Jpmorgan Chase & Co, State Street Corp, Baillie Gifford & Co., and Geode Capital Management, L.L.C.